DHCR7 and neoplasm: For example, DHCR7 overexpression correlates with poor prognosis in cervical, gastric, breast, and bladder cancers [4, 5, 6, 7], while loss‐of‐function mutations (e.g., rs104886035/rs104886038) disrupt cholesterol metabolism to suppress tumor growth [5].